-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In recent years, the bio-industry represented by bio-pharmaceuticals is accelerating its development, and its industrial innovation capability has been continuously enhanced
.
On April 12, the Shanghai Stock Exchange and China Securities Index Co.
, Ltd.
officially announced the relevant arrangements for the release of the SSE Science and Technology Innovation Board Biomedical Index (referred to as the Kechuang Bio Index)
.
After liquidity screening, the Kechuang Bio Index selects 50 securities of companies in the fields of biomedicine and biomedical engineering with large market capitalization as index samples
.
The Science and Technology Creation Biological Index is another major industry theme index representing the Science and Technology Innovation Board market after the Science and Technology Innovation 50 Index and the Science and Technology Innovation Information Index, which will further enrich the index system of the Science and Technology Innovation Board market
.
The Shanghai Stock Exchange stated that it will continue to improve the STAR Market Index system and provide the market with more dimensions of performance benchmarks and investment targets
.
Benefiting from institutional innovation, the Science and Technology Innovation Board has become an important listing place for biopharmaceutical industry companies
.
Up to now, 90 technological innovation enterprises in biomedicine-related industries have been listed on the Science and Technology Innovation Board
.
According to the announcement of the Shanghai Stock Exchange and China Securities Index Co.
, Ltd.
on April 12, the SSE Science and Technology Innovation Board Biomedical Index will be officially released on May 9
.
It is reported that the top five heavyweight stocks are Junshi Bio, Oriental Bio, CanSino, Medicilon and Haier Bio, with a combined weight of 33%
.
Among them, Junshi Bio is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs, as well as clinical research and development and commercialization on a global scale
.
The data shows that Junshi Bio’s revenue is mainly composed of drug sales revenue and external licensing revenue
.
In 2021, Junshi Bio’s operating income increased by 152.
4% year-on-year to 4.
02 billion yuan
.
During the performance period, Junshi Biotechnology continued to expand its R&D investment, and the annual R&D expenses reached 2.
068 billion yuan, a year-on-year increase of 16.
35%
.
Orient Bio is an enterprise that develops, produces and sells in vitro diagnostic reagents based on genetic diagnosis technology and new anti-cancer drugs based on gene therapy.
research, production and sales
.
CanSino's main business is the research and development, production and commercialization of innovative vaccines that meet Chinese and international standards
.
The company's main products are Ebola virus disease vaccine, meningitis vaccine, DTP vaccine, pneumonia vaccine, tuberculosis vaccine, herpes zoster vaccine, adenovirus vaccine, polio vaccine,
etc.
In 2021, the company will achieve an annual operating income of approximately RMB 4.
3 billion, a net profit attributable to the parent of more than RMB 1.
9 billion, and a net cash flow generated by operating activities of more than RMB 2 billion, successfully turning losses into profits
.
Medicilon focuses on the CRO of biopharmaceutical preclinical comprehensive research and development services, and has formed a relatively obvious market competitiveness and a certain market position
.
Data shows that in 2021, the company's operating income will increase by 75.
28% year-on-year, or about 1.
167 billion yuan; the net profit attributable to shareholders of listed companies will increase by 118.
12% year-on-year, or about 282 million yuan
.
Haier Bio's business started from the research and development, production and sales of biomedical cryogenic storage equipment.
It is a comprehensive biosafety solution service provider based on the transformation of the Internet of Things.
Its main businesses include: sample safety, drug and reagent safety, vaccine safety, blood safety, etc.
The scenario provides biomedical cryogenic storage solutions covering the full temperature range from -196°C to normal temperature, as well as automated, intelligent and comprehensive upgrades based on user needs, and provides comprehensive solutions for IoT scenarios covering multiple types of biosafety products
.
Analysts pointed out that the current listed biopharmaceutical companies on the Science and Technology Innovation Board have the attributes of low valuation, high growth, and high R&D, and the investment value is obvious
.
Biomedicine is also one of the industry themes with outstanding overall profitability on the Science and Technology Innovation Board
.
Another person pointed out that China's biopharmaceutical industry is currently undergoing innovation from quantity to quality.
New products are being launched one after another.
At the same time, consumption upgrades continue to bring about new demand releases.
The resonance between rigid demand and optional demand will promote the continuous improvement of the industrial structure.
optimize
.
In addition, according to the financial reports of biopharmaceutical companies in 2021, the performance of biopharmaceutical companies on the Science and Technology Innovation Board in 2021 will maintain a rapid growth rate, with a year-on-year increase of 54% (after excluding losses)
.
The median gross margin was 73% and the median net profit margin was 24%
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
.
On April 12, the Shanghai Stock Exchange and China Securities Index Co.
, Ltd.
officially announced the relevant arrangements for the release of the SSE Science and Technology Innovation Board Biomedical Index (referred to as the Kechuang Bio Index)
.
After liquidity screening, the Kechuang Bio Index selects 50 securities of companies in the fields of biomedicine and biomedical engineering with large market capitalization as index samples
.
The Science and Technology Creation Biological Index is another major industry theme index representing the Science and Technology Innovation Board market after the Science and Technology Innovation 50 Index and the Science and Technology Innovation Information Index, which will further enrich the index system of the Science and Technology Innovation Board market
.
The Shanghai Stock Exchange stated that it will continue to improve the STAR Market Index system and provide the market with more dimensions of performance benchmarks and investment targets
.
Benefiting from institutional innovation, the Science and Technology Innovation Board has become an important listing place for biopharmaceutical industry companies
.
Up to now, 90 technological innovation enterprises in biomedicine-related industries have been listed on the Science and Technology Innovation Board
.
According to the announcement of the Shanghai Stock Exchange and China Securities Index Co.
, Ltd.
on April 12, the SSE Science and Technology Innovation Board Biomedical Index will be officially released on May 9
.
It is reported that the top five heavyweight stocks are Junshi Bio, Oriental Bio, CanSino, Medicilon and Haier Bio, with a combined weight of 33%
.
Among them, Junshi Bio is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs, as well as clinical research and development and commercialization on a global scale
.
The data shows that Junshi Bio’s revenue is mainly composed of drug sales revenue and external licensing revenue
.
In 2021, Junshi Bio’s operating income increased by 152.
4% year-on-year to 4.
02 billion yuan
.
During the performance period, Junshi Biotechnology continued to expand its R&D investment, and the annual R&D expenses reached 2.
068 billion yuan, a year-on-year increase of 16.
35%
.
Orient Bio is an enterprise that develops, produces and sells in vitro diagnostic reagents based on genetic diagnosis technology and new anti-cancer drugs based on gene therapy.
research, production and sales
.
CanSino's main business is the research and development, production and commercialization of innovative vaccines that meet Chinese and international standards
.
The company's main products are Ebola virus disease vaccine, meningitis vaccine, DTP vaccine, pneumonia vaccine, tuberculosis vaccine, herpes zoster vaccine, adenovirus vaccine, polio vaccine,
etc.
In 2021, the company will achieve an annual operating income of approximately RMB 4.
3 billion, a net profit attributable to the parent of more than RMB 1.
9 billion, and a net cash flow generated by operating activities of more than RMB 2 billion, successfully turning losses into profits
.
Medicilon focuses on the CRO of biopharmaceutical preclinical comprehensive research and development services, and has formed a relatively obvious market competitiveness and a certain market position
.
Data shows that in 2021, the company's operating income will increase by 75.
28% year-on-year, or about 1.
167 billion yuan; the net profit attributable to shareholders of listed companies will increase by 118.
12% year-on-year, or about 282 million yuan
.
Haier Bio's business started from the research and development, production and sales of biomedical cryogenic storage equipment.
It is a comprehensive biosafety solution service provider based on the transformation of the Internet of Things.
Its main businesses include: sample safety, drug and reagent safety, vaccine safety, blood safety, etc.
The scenario provides biomedical cryogenic storage solutions covering the full temperature range from -196°C to normal temperature, as well as automated, intelligent and comprehensive upgrades based on user needs, and provides comprehensive solutions for IoT scenarios covering multiple types of biosafety products
.
Analysts pointed out that the current listed biopharmaceutical companies on the Science and Technology Innovation Board have the attributes of low valuation, high growth, and high R&D, and the investment value is obvious
.
Biomedicine is also one of the industry themes with outstanding overall profitability on the Science and Technology Innovation Board
.
Another person pointed out that China's biopharmaceutical industry is currently undergoing innovation from quantity to quality.
New products are being launched one after another.
At the same time, consumption upgrades continue to bring about new demand releases.
The resonance between rigid demand and optional demand will promote the continuous improvement of the industrial structure.
optimize
.
In addition, according to the financial reports of biopharmaceutical companies in 2021, the performance of biopharmaceutical companies on the Science and Technology Innovation Board in 2021 will maintain a rapid growth rate, with a year-on-year increase of 54% (after excluding losses)
.
The median gross margin was 73% and the median net profit margin was 24%
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
